|
|
 |
|
Viewing report
|
|
|
|
Immunomodulators: Therapeutic Needs, Pipelines & Prospects
Business Insights, Aug 2007, Pages: 345
The modulation of immune system activity is a required pharmacological intervention for many medical conditions, bearing particular importance in the treatment of autoimmune diseases and allergies and transplant procedures. With traditional immunomodulatory drugs continuing to exhibit limited efficacy and adverse side effects, the drive to develop new, improved, and specifically targeted immunotherapies has been gaining momentum. ‘Immunomodulators: Therapeutic Needs, Pipelines & Prospects’ is a new report published by Business Insights that provides a detailed examination of the current market for immunomodulatory therapies. The strategies and technologies used in immunomodulation are analysed and the major clinical applications of immunomodulators are reviewed to identify the leading drug classes and most promising agents currently in development. This report will also investigate patient metrics and provide market forecasts for immunomodulators to 2011.
Key findings...
-The market for immunomodulators was valued at $43bn in 2006, and is expected to grow at a CAGR of 13% to reach $80bn by 2011.
-Pipeline immunomodulators mainly consist of biopharmaceuticals such as recombinant proteins, vaccines and monoclonal antibodies, but also include several small molecules.
-In inflammatory and autoimmune disorders, immunomodulators in clinical development are predominantly aimed at GCPR’s, leukocyte surface antigens, cytokines and kinases.
-Clinical trials for infectious diseases are focused upon prophylactic vaccines. However, the treatment of HIV and HCV infections has also warranted the development of therapeutic vaccines.
-Immunostimulation marks a dynamic change in cancer treatments. Two prophylactic cancer vaccines have been approved and several therapeutic vaccines are in clinical and preclinical development.
-Co-stimulation blockers promise to become the new standard of post-transplantation immunosuppression.
Key Questions Answered….
-How is the immunomodulator market structured?
-What were the leading immunomodulator drug classes in 2006?
-Which immunomodulator drug classes will dominate the market?
in 2010?
-What types of immunomodulators are in clinical development for:
-- Inflammatory and Autoimmune disorders?
-- Infectious Diseases?
-- Cancer?
-Who are the pharmaceutical and biotechnology companies that are set to become the future market leaders?
-Which companies were the most influential signees of immunomodulatory US patents?
Key issues examined in this report….
-Concerns over traditional immunomodulators. Agents in development are set to enhance safety and specificity, and may also be administered over a more convenient time-course.
-Opportunities in inflammation. The inflammation pathway offers a range of promising targets for the development of new immunomodulator drugs.
-New approaches to vaccine development. Sub-unit and DNA vaccines have emerged to address the ineffectiveness of traditional vaccines in inducing cell-mediated immunity.
-Biological response modifiers. Widespread debate has been evoked over the capabilities of immune systems in eliminating cancer cells. Cytokines, monoclonal antibodies and therapeutic vaccines are set to enhance this function.
-Developments in immunosuppression therapy. Co-stimulatory blockers are a class of immunomodulators under investigation for chronic maintenance therapy.
Customers who bought this item also bought
Building on Early Successes of Immunomodulators in the Fight Against Cancer
Carbohydrate-Based Vaccines and Immunotherapies
Cancer Vaccines and Tumor Immunity
Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer
Human Vaccines - Global Strategic Business Report
Therapeutic Monoclonal Antibodies Markets
Cancer Cell Therapy Markets
Therapeutic Vaccines for Cancer: On the Threshold of Success
Cancer Vaccines: Measuring Market Potential
U.S. Cancer Vaccines Market
Competitive Outlook on Non-Antibody Based Cancer Vaccines
Building Better Cancer Vaccines: The Progress and Promise of R&D
|
|
|
|
